Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with drug-resistant infections in 2022. While there is still no vaccine for the virus, the twice-yearly injectable is “the next best thing,” according to the World Health Organization. However, even before the drug was approved, it was known that the virus could develop resistance to it, though this was rare. But now, a new study published in the journal Science Translational Medicine has shown that this resistance comes at a cost to the virus’s ability to survive and replicate.
This article was originally published on MedicalXpress.com
